RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened

• Rhythm Pharmaceuticals, Inc. (RYTM) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company issued a press release dated February 26, 2026, and furnished the full text of that release as Exhibit 99.1 to its Current Report on Form 8-K (filed Feb 26, 2026).

Key Details

• Filing date: February 26, 2026 (Form 8-K; Accession No. 0001628280-26-011987).
• Reporting period: fourth quarter and full year ended December 31, 2025.
• The press release containing the results is provided as Exhibit 99.1 to the 8-K (Item 2.02 Results of Operations and Financial Condition; Item 9.01 Exhibits).
• The 8-K furnishes the announcement; investors should consult Exhibit 99.1 for the full financial figures and management commentary.

Why It Matters

• Quarterly and full-year results disclose key financial metrics—revenue, profitability, and cash position—that affect Rhythm’s valuation and operational runway.
• This 8-K signals where to find the company’s most recent performance data; investors should review the press release (Exhibit 99.1) and any related earnings presentation or subsequent SEC filings for details on revenue, expenses, guidance, and any management statements.